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OBJECTIVE: To estimate the cost-effectiveness of cetuximab in
combination with radiotherapy (ERT) compared to radiotherapy
alone (RT), for the treatment of locally advanced head and neck
cancer in patients for whom chemoradiotherapy is inappropri-
ate or intolerable in France. METHODS: A modelled economic
evaluation calculated the incremental cost per quality-adjusted
life year (QALYs) gained with ERT compared to RT. Resource
utilisation and survival data were extracted from an interna-
tional phase-III trial of ERT. Assumptions regarding costs of care
were drawn from estimates by an expert clinical panel. Overall
survival and progression-free survival times were extrapolated
beyond the trial period using statistical models. Patient survival
was stratiﬁed into health states deﬁned by adverse event status
in the acute phase and disease status post-treatment. Utility
values for the health states were obtained from a survey of oncol-
ogy nurses using the EQ-5D. Estimates of individual costs and
outcomes were estimated for each patient in the trial and overall
mean values calculated for the incremental analysis between the
treatment groups. The analysis was conducted from the per-
spective of the public and private French healthcare system.
Costs and outcomes were discounted at 3.5%. RESULTS: In the
lifetime analysis, ERT patients were estimated to gain an extra
1.07 QALYs compared to RT patients. From the public estab-
lishment perspective, this translated into an incremental cost per
QALY gained of €10,927. Shortening the analysis to the time-
frame of the clinical trial (5 years) raised the ICERs to €31,355
per QALY gained respectively. Bootstrap simulation and sensi-
tivity analysis showed that the ICERs were robust to changes in
the key variables. CONCLUSIONS: Results of the modeled eco-
nomic evaluation strongly suggest that ERT offers a good value-
for-money alternative in the treatment of locally advanced head
and neck cancer in France.
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OBJECTIVES: Primary (ﬁrst and subsequent cycles) prophylaxis
with colony stimulating factors is recommended in the 2006
ASCO and EORTC clinical guidelines when the risk of febrile
neutropenia (FN) is ≥20%. In clinical practice, ﬁlgrastim has
often been used for fewer than the recommended 11 days, which
has been shown to compromise clinical outcomes. This study
evaluated the cost-utility of pegﬁlgrastim vs. ﬁlgrastim (11- or 6-
days) primary prophylaxis in women with breast cancer receiv-
ing chemotherapy with ≥20% FN risk in the UK. METHODS:
We constructed a decision-analytic model from a payer’s per-
spective. Costs were from ofﬁcial list prices or literature and
included drugs, drug administration, FN-related hospitalisations
and subsequent medical costs. FN risk (varied by days of ﬁl-
grastim), FN case-fatality, relative dose intensity (RDI), the
impact of RDI on survival, and utility scores were based on a
comprehensive literature review and expert panel validation.
Breast cancer mortality and all-cause mortality were obtained
from ofﬁcial statistics. Model robustness was tested using multi-
way sensitivity analyses. RESULTS: Pegﬁlgrastim was cost-
saving in addition to being more effective than 11-day ﬁlgrastim.
Compared with 6-day ﬁlgrastim, pegﬁlgrastim achieved 0.107
more QALYs (15.139 vs. 15.032 QALY) at a minimal cost
increase of ≤446 (≤3193 vs. ≤2747) per person; the incremental
cost-utility ratio was ≤4166/QALY. Pegﬁlgrastim decreased the
absolute risk of FN by 10.5% (17.5% vs. 7%), and was associ-
ated with ≤4246 per FN avoided or ≤42 per 1% decrease in
absolute risk of FN. Age of diagnosis and cancer stage had
minimal impact on the results. The results were sensitive to 
the costs of drugs and risk of FN. CONCLUSIONS: Use of 
pegﬁlgrastim in the UK appeared to dominate 11-day use of 
ﬁlgrastim. The value of pegﬁlgrastim vs. 6-day ﬁlgrastim 
at ≤4166/QALY is very favourable compared with the cost-
effectiveness threshold commonly used in the UK HTA setting.
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OBJECTIVES: Imatinib combined with conventional
chemotherapy (CC) in Ph+ALL patients has produced encourag-
ing efﬁcacy results with a well-tolerated safety proﬁle. This study
explores the cost effectiveness of imatinib plus CC versus CC
alone in adult Ph+ALL patients. METHODS: A Markov model
simulated a hypothetical cohort of adult Ph+ALL patients receiv-
ing imatinib plus CC or CC alone. The model included three
states: alive without disease progression (DFS), alive with disease
progression (DS), and death. State transition probabilities were
derived from the published literature. In the absence of relevant
data pertaining to Ph+ALL, assumptions about costs and utilities
were derived from a cost analysis of CML. Only direct medical
costs were included, adopting a UK health care payer perspec-
tive. All outcomes were discounted. An adaptation of the model
to the US perspective was conducted as well. RESULTS: The
model projects that the total discounted survival was 1.10 years
for CC and 4.31 years for imatinib+CC. Total discounted disease
free survival was 0.76 year for CC and 2.77 years for ima-
tinib+CC. The total discounted quality adjusted life years
(QALY) were 0.85 v. 3.28 for CC and imatinib+CC, respectively.
Thus, the net incremental gain in discounted quality adjusted
survival was 2.43 QALYs. The monthly costs of DFS and DS
were estimated at £123 and £417, respectively. The net costs
associated with imatinib were £51,757 for the UK. The incre-
mental cost per QALY of imatinib+CC v. CC alone was approx-
imately £21,290 (i.e., £51,757 divided by 2.43 QALYs).
Adapting the model to the US perspective, the incremental cost
per QALY was about $42,000. CONCLUSIONS: For adult ALL
patients with poor prognosis due to Ph+ALL, our exploratory
analysis suggests that, given the underlying data and assump-
tions, adding imatinib to current chemotherapy regimens is cost-
effective compared to chemotherapy alone both from the UK and
the US perspectives.
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